KOSDAQBiotech & Pharma225430

Kmpharmaceutical

₩698 0.00%2026-11-18 close
Market Cap
₩4.5B
Turnover
₩0
Volume
0 shares
Shares out.
6.5M
PER
—
PBR
0.2×
EPS
-₩602
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

KM PHARMACEUTICAL: Narrowing Losses, Unresolved Listing Status

KM PHARMACEUTICAL's operating loss in the third quarter of 2026 was smaller than a year earlier, but the continuing loss record and the outcome of the delisting dispute remain open items to verify.

  1. 1

    First-half 2026 revenue reached about KRW 8.3 billion, up 13.4% year on year, according to the company's August 2026 disclosure. Third-quarter revenue of KRW 4.03 billion fell 8.0% year on year, so the quarterly trend is mixed.

  2. 2

    The 2025 operating loss was KRW 2.92 billion with an operating margin of -18.3%, and the company has recorded losses in each of the four years from 2022 to 2025.

  3. 3

    After the September 14, 2026 delisting decision, the Seoul Southern District Court granted a suspension of the decision on October 2, 2026, and the exchange promptly filed an objection.

  4. 4

    The company plans to expand capacity in stages through 2028 to reach a production system of up to KRW 90 billion on a 24-hour operating basis.

  5. 5

    In July 2026 the company completed a roughly KRW 1 billion third-party rights offering in which the CEO took part with personal funds, and in August it began open-market purchases of treasury shares worth about KRW 300 million.

02

Business structure

KM PHARMACEUTICAL is a life-care company that makes oral care and cosmetic products at its Pyeongtaek site in Gyeonggi Province. The CEO said more than 80% of current revenue comes from its OEM and ODM business.

The Pyeongtaek plant is split into a first factory for medicated toothpaste and toothbrushes and a second factory for skincare, body and hair care products.

According to an Edaily report, the first factory already operates above its practical capacity because of orders from large domestic pharmaceutical companies and overseas brands.

Its own brands include the children's oral care line 'Pororo Toothpaste', the oral care brand FOAMGLE, and the scalp and hair care brand Zerocipe, and own-brand sales still make up less than 20% of revenue. The company has set a target of raising that share to about 50% within three years.

The nanographene material at the core of Zerocipe completed its patent registration in June 2026, according to the company. Sales through the Olive Young channel began after the product entered it in November 2024, as the company explained.

Overseas revenue rests mainly on a distribution deal in Malaysia, shipments of Pororo toothpaste to Vietnam and China, and a collaboration with a Swiss natural cosmetics company, whose cumulative production revenue an industry report put above KRW 7 billion.

Customers include domestic pharmaceutical and household goods companies as well as overseas brand owners, so changes in orders from a single client flow quickly into quarterly revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.4B-₩800M−18.5%
2025Q4₩4.3B-₩900M−19.8%
2026Q1₩4.5B-₩700M−14.7%
2026Q2₩3.8B-₩600M−15.3%
2026Q3₩4B-₩500M−11.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩15.6B-₩1.2B-₩3.9B−8.0%−10.8%41.2%
2023₩17.8B-₩1.1B-₩1.3B−6.1%−3.7%42.5%
2024₩14.5B-₩2.6B-₩4.6B−17.7%−14.0%50.2%
2025₩16B-₩2.9B-₩4B−18.3%−14.0%64.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 15.6 billion in 2022 to KRW 17.8 billion in 2023 (up 13.7% year on year), fell to KRW 14.5 billion in 2024 (down 18.5%), and recovered to KRW 16 billion in 2025 (up 10.5%). Among the years 2022 to 2025, 2023 was the largest year and 2024 was the smallest.

The operating loss was KRW 1.25 billion in 2022, KRW 1.09 billion in 2023, KRW 2.57 billion in 2024 and KRW 2.92 billion in 2025, with operating margins of -8.0%, -6.1%, -17.7% and -18.3%. In 2024 and 2025 both the loss amount and the margin worsened.

Net loss attributable to controlling shareholders was KRW 3.92 billion in 2022, KRW 1.32 billion in 2023, KRW 4.57 billion in 2024 and KRW 3.97 billion in 2025, and the net loss including non-controlling interests was disclosed at the same amounts.

The debt ratio rose from 41.2% in 2022 to 64.1% in 2025, and year-end 2025 total equity of KRW 28.3 billion was entirely attributable to controlling shareholders, against total liabilities of KRW 18.1 billion.

An Edaily report noted that revenue of KRW 22.9 billion in 2020 and KRW 22.7 billion in 2021 fell to KRW 15.6 billion in 2022, when the company moved into operating losses. The CEO attributed the operating losses to R&D and brand marketing costs that were concentrated temporarily.

On a quarterly basis, the operating loss widened from KRW 809 million in the third quarter of 2025 and KRW 851 million in the fourth quarter to KRW 659 million, KRW 585 million and KRW 454 million in the first three quarters of 2026.

Quarterly revenue moved up and down across KRW 4.38 billion, KRW 4.29 billion, KRW 4.47 billion, KRW 3.84 billion and KRW 4.03 billion from the third quarter of 2025 to the third quarter of 2026.

The first- and second-quarter 2026 figures add up to the first-half revenue of about KRW 8.3 billion that the company disclosed in August 2026.

Net loss attributable to controlling shareholders was KRW 705 million in the third quarter of 2026, and the total for the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, was KRW 3.46 billion.

Five consecutive quarters of losses, from the third quarter of 2025 through the third quarter of 2026, are on record.

05

Industry analysis

In domestic oral care OEM and ODM, orders from large pharmaceutical companies determine how much of the production capacity is used. According to an Edaily report, the first factory at KM PHARMACEUTICAL already operates above its practical capacity, and the company is pursuing expansion on the second factory site.

In cosmetics OEM and ODM, the company says inquiries from domestic and overseas brands are increasing, as reported by Sisa Week in March 2026. Overseas, the company said it has a Malaysian exclusive distribution agreement and is in supply talks in Thailand.

Shipments of Pororo Toothpaste reached about 180,000 units to Vietnam in the second quarter of 2026, and about 300,000 units were shipped to China from January to April 2026. In the United States, the company has kept its FDA cGMP facility certification since 2019 and completed the maintenance procedure in 2026.

Compared with Samsung Biologics and other listed companies in the biopharma sector that center on contract manufacturing for drugs, KM PHARMACEUTICAL focuses on quasi-drug and cosmetics production, so its earnings structure and customer concentration differ.

In competition, it faces large oral care manufacturers in toothpaste OEM and specialized firms in cosmetics OEM. The company presents its nanographene material as a point of differentiation in scalp and hair care.

06

Outlook

The company attributed first-half 2026 revenue growth to new OEM and ODM orders and overseas shipments of its own brands, and said it will widen export destinations to emerging markets such as the Middle East and South America in the second half.

Edaily reported that the CEO set a target of more than KRW 20 billion in revenue for 2026. Quarterly revenue stayed in the range of roughly KRW 4 billion from the first quarter to the third quarter of 2026, so whether the target is reached will be confirmed in the 2026 annual report.

On capacity, the company plans to expand equipment in stages through 2028 to reach annual output of about KRW 30 billion on an eight-hour basis and up to KRW 90 billion on a 24-hour basis.

The CEO cited reaching KRW 50 billion in annual revenue as the first target for 2028 and said the longer-term aim is about KRW 100 billion. The company aims to lift own-brand sales to about 50% of revenue within three years, expanding into dermo-cosmetics and aesthetic products such as skin boosters.

A toothpaste and toothbrush line using the Haechi character, along with functional cosmetics and household goods, was presented as second-half 2026 plans.

A March 2026 report said a scalp treatment product developed with a UK hair clinic was targeted for launch in summer 2026, and whether it launched is a point to confirm through company disclosures and press reports.

The company said the proceeds of the July 2026 rights offering will fund operating capital for new growth businesses, production equipment and balance sheet stability. The next checkpoints are the full-year operating loss to appear in the 2026 annual report and progress on the 2028 capacity expansion.

07

Valuation

PER
—
PBR
0.2×
ROE
-12.3%
EPS
-₩602
BPS
₩4,111
Dividend per share
₩0

The current PER cannot be calculated because of the net losses over the most recent four quarters. The price-to-book ratio places the share price at a low level relative to net assets, and market capitalization sits well below total equity at the end of 2025.

Because earnings-based multiples cannot be calculated, comparisons based on assets carry more weight. The dividend level is below the industry average. The July 2026 rights offering raised the share count from 5,577,410 shares to 6,485,675 shares, which changes per-share comparisons.

In July 2026 the company announced a treasury share purchase plan and said it judged the current share price to be low relative to its growth potential and intrinsic value.

The meaning of the same share price will change depending on the outcome of the suspension of the delisting decision and on whether trading resumes.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Signs of improvement in sales and losses

The company disclosed in August 2026 that first-half 2026 revenue reached about KRW 8.3 billion, up 13.4% year on year. It attributed the increase to new OEM and ODM orders and overseas shipments of its own brands.

The operating loss narrowed to KRW 659 million in the first quarter of 2026, KRW 585 million in the second and KRW 454 million in the third.

Planned capacity expansion

The company plans to complete equipment expansion by 2028 to reach a production system of up to KRW 90 billion on a 24-hour basis. Because the first factory already runs above capacity, it describes the second-factory expansion as a means of meeting larger order volumes. It set annual revenue of KRW 50 billion as the first target for 2028.

Overseas demand and partnerships

The company said about 180,000 units of Pororo Toothpaste shipped to Vietnam in the second quarter of 2026, and about 300,000 units shipped to China from January to April 2026.

An industry report said cumulative production revenue from a Swiss natural cosmetics partnership passed KRW 7 billion, with order volume up more than 40% year on year. The company plans to widen export markets to the Middle East and South America in the second half.

09

Bear factors

Continuing losses and low operating margins

On a disclosed basis the company posted operating losses from 2022 through 2025, and the 2025 operating margin was -18.3%. Five consecutive quarters of losses are on record through the third quarter of 2026. The debt ratio rose from 41.2% in 2022 to 64.1% in 2025.

Listing procedure and administrative-issue risk

The September 14, 2026 delisting decision was suspended until a final judgment after the Seoul Southern District Court granted an injunction on October 2, 2026. The exchange has filed an objection, and the review is ongoing. CEO Baik Seung-won has named lifting the administrative-issue designation as the top management priority.

Dilution and a third-quarter revenue decline

The July 2026 rights offering raised the share count from 5,577,410 to 6,485,675 shares. Third-quarter 2026 revenue of KRW 4.03 billion fell 8.0% year on year. Growth in the first half turned into a decline in the third quarter, so whether the trend holds needs confirmation in further quarters.

10

Risk factors

Listing and legal risk

The delisting decision is suspended only until a final judgment, and whether the stock stays listed will depend on the court's ruling and the outcome of the exchange's objection. NewsTomato reported that trading in KM PHARMACEUTICAL remains suspended. The timing of any trading resumption will also depend on the court's ruling and the exchange's decision.

Customer and production concentration

OEM and ODM make up more than 80% of revenue, so changes in orders from large domestic pharmaceutical companies flow directly into sales. The first factory operates above capacity, so production disruption could affect order fulfilment. Own-brand sales remain below 20% of revenue, a wide gap from the roughly 50% level the company is targeting.

Capacity funding and execution risk

Expansion will proceed in stages through 2028 and must pass facility certification and permit procedures. The company said proceeds from the July 2026 rights offering will fund operating capital and equipment investment. If expansion or margin improvement is delayed, the possibility of further capital raising remains.

11

What to watch next

  1. After December 2026 (date not set)

    Outcome of the main lawsuit over the suspended delisting decision and the exchange's objection review. This event determines whether the listing is maintained and whether trading can resume.

  2. Date not set (after November 2026)

    Whether the administrative-issue designation is lifted, which the CEO named as the top priority. Whether the exchange's criteria are met is the point to confirm.

  3. End of March 2027

    Filing of the 2026 annual report. It will be the first confirmed source for full-year 2026 revenue, operating loss and fourth-quarter results, and will show whether the operating losses recorded since 2022 continue.

  4. 2028

    Completion of the second-factory expansion and progress toward the first target of KRW 50 billion in annual revenue. This shows whether added capacity translates into higher sales.

12

Overall view

KM PHARMACEUTICAL recorded operating losses from 2022 through 2025, and quarterly operating losses narrowed in 2026 to KRW 454 million in the third quarter. First-half 2026 revenue reached about KRW 8.3 billion, up 13.4% year on year, while third-quarter 2026 revenue of KRW 4.03 billion fell 8.0% year on year.

New OEM and ODM orders, overseas shipments of own brands and the Pyeongtaek capacity plan are cited as growth drivers. On the other side, the 2025 operating margin was -18.3%, and five consecutive quarters of losses from the third quarter of 2025 are on record.

On listing status, a delisting decision dated September 14, 2026 was followed by a court injunction on October 2, 2026, and the exchange's objection is under review. Whether trading resumes is a matter to confirm through exchange disclosures.

On valuation, earnings-based multiples cannot be calculated, and the share price sits at a low level relative to net assets. The next checkpoints are the outcome of the listing procedure, the full-year operating loss in the 2026 annual report, and progress on the 2028 expansion and the KRW 50 billion revenue target.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. markets.hankyung.com
  3. m.news.nate.com
  4. pharm.edaily.co.kr
  5. m.news.nate.com
  6. saramin.co.kr
  7. view.asiae.co.kr
  8. v.daum.net
  9. increasing-words.com
  10. v.daum.net
  11. news.nate.com
  12. m.news.nate.com
  13. sedaily.com
  14. news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. sedaily.com
  18. m.news.nate.com

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis